secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001213900-23-001518
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics appoints Cedric O'Gorman MD as Chief Medical Officer
-------------------------------------------------------------------------

- Dr. O'Gorman appointed CMO effective January 9, 2023, leading medical, clinical, and regulatory for REL-1017 MDD program.
- He brings over 20 years CNS experience; previously CMO at Alpha Cognition and SVP at Axsome Therapeutics.
- CEO cites his expertise with similar-mechanism antidepressants and key regulatory discussions ahead.
- Corporate presentation updated and filed as Exhibit 99.2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023001518/0001213900-23-001518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023001518/ea171401-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-001518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer